GRAIL
GRALServices-Medical Laboratories · Avg daily volume 1.1M · fiscal year ends Dec$157.88+7.27+4.83%Volume 1.2M+4% vs avg
10-day20-day50-day200-dayRS line vs S&P 500▲ earnings filed, EPS vs a year agoQ3 EPS due in ~15 days
2026-10-28O 150.61 H 160.25 L 149.37 C 157.88 (+4.83%)Vol 1.2M10 134.1020 136.5850 108.23200 77.57RS line 20.4RS rating 99
| FY (Dec) | EPS $ | Chg | High | Low |
|---|---|---|---|---|
| 2022 | -173.89 | – | – | – |
| 2023 | -47.21 | +73% | – | – |
| 2024 | -63.54 | −35% | – | – |
| 2025 | -11.11 | +83% | 116 | 17 |
| TTM | -9.74 | 166 | 42 |
Ratings & facts
RS Rating99 ▲1
Days at RS 90+23
Setup checks3 / 3
EPS chg, last qtr+20%
EPS acceleratingno
Sales chg, last qtr+26%
P/E (last 4 qtrs)–
Mkt cap$7.05B
Off 52-wk high-5.2%
Quarterly earnings
Latest filing: 10-Q, 2026-08-06Mar ’24FQ1 ’24
Jun ’24FQ2 ’24
Sep ’24FQ3 ’24
Dec ’24Q4FQ4 ’24
Mar ’25FQ1 ’25
Jun ’25FQ2 ’25
Sep ’25FQ3 ’25
Dec ’25Q4FQ4 ’25
Mar ’26FQ1 ’26
Jun ’26FQ2 ’26
EPS
EPS
−$7.05
−$51.06
−$3.94
−$2.89
−$3.10
−$3.18
−$2.46
−$2.43
−$2.29
−$2.56
% chg
–
−721%
+86%
+52%
+56%
+94%
+38%
+16%
+26%
+20%
Sales
26.7M
32.0M
28.7M
38.3M
31.8M
35.5M
36.2M
43.6M
40.8M
44.7M
% chg
–
+43%
+38%
+26%
+19%
+11%
+26%
+14%
+28%
+26%
Filed
05/14
08/13
11/13
03/05
05/14
08/13
11/13
03/12
05/07
08/06
EPS growth ≥ 25%0–25%fallingno comparison
Source: SEC EDGAR 10-Q and 10-K filings, loaded the first time a stock is opened and refreshed daily. Q4 = full year minus the first three quarters. Growth from a loss is measured against the size of the loss (−$1 → $2 = +300%). Analyst estimates are not in EDGAR.